Since evaluation of novel IPF therapies poses considerable challenges in selecting outcome measures that allow assessment of clinically meaningful effects, we also investigated whether the extracellular enzyme, lysyl oxidase (LOX) has potential to act as a biomarker for evaluation of the anti-fibrotic effects of romidepsin. This evidence concerns the gene LOX and idiopathic pulmonary fibrosis.